Mix and match: Chemo, antiangiogenic combos equal in metastatic CRC
AT THE ASCO ANNUAL MEETING 2014
"Chemotherapy choice is a choice that is very much market driven in the United States: 75% of patients received FOLFOX. That’s based on sort of a habit as much as anything else, and I hope that this study might raise the other possibility with FOLFIRI," he said at a media briefing earlier in the day.
The study was funded by the National Cancer Institute. Dr. Venook disclosed serving as an uncompensated advisor to several companies including Bristol-Myers Squibb, maker of cetuximab, and Roche/Genetech, maker of bevacizumab. Dr. Tabernero has disclosed serving on advisory boards for Sanofi-Aventis, Pfizer, Roche and Merck. Dr. Hudis served as a data and safety management board chair for Genentech and received research grants from Onyx Pharmaceuticals and Merck.
